ATE454382T1 - Verbindungen mit selektiverinhibierender wirkung für gsk3 - Google Patents

Verbindungen mit selektiverinhibierender wirkung für gsk3

Info

Publication number: ATE454382T1
Authority: AT; Austria
Prior art keywords: compounds; alkylnr; gsk3; alkylc; solvate
Prior art date: 2002-12-17

Application number

AT03781204T

Other languages

English (en)

Inventor

Stefan Berg

Sven Hellberg

Peter Soederman

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-17

Filing date

2003-12-15

Publication date

2010-01-15

2003-12-15 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2010-01-15 Application granted granted Critical

2010-01-15 Publication of ATE454382T1 publication Critical patent/ATE454382T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 4
102000001267 GSK3 Human genes 0.000 title 1
108060006662 GSK3 Proteins 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 title 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
239000012453 solvate Substances 0.000 abstract 2
125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
125000002877 alkyl aryl group Chemical group 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
239000012458 free base Substances 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Immunology (AREA)
Psychiatry (AREA)
Virology (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Psychology (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Gynecology & Obstetrics (AREA)
AIDS & HIV (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)

AT03781204T 2002-12-17 2003-12-15 Verbindungen mit selektiverinhibierender wirkung für gsk3 ATE454382T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE0203754A SE0203754D0 (sv)	2002-12-17	2002-12-17	New compounds
PCT/SE2003/001955 WO2004055005A1 (en)	2002-12-17	2003-12-15	Novel compounds having selective inhibiting effect at gsk3

Publications (1)

Publication Number	Publication Date
ATE454382T1 true ATE454382T1 (de)	2010-01-15

Family

ID=20289907

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03781204T ATE454382T1 (de)	2002-12-17	2003-12-15	Verbindungen mit selektiverinhibierender wirkung für gsk3

Country Status (18)

Country	Link
US (2)	US7585853B2 (de)
EP (2)	EP2161265A3 (de)
JP (1)	JP4674088B2 (de)
KR (1)	KR101110457B1 (de)
CN (1)	CN100351250C (de)
AT (1)	ATE454382T1 (de)
AU (1)	AU2003287135B2 (de)
BR (1)	BR0317294A (de)
CA (1)	CA2508042C (de)
DE (1)	DE60330910D1 (de)
ES (1)	ES2337682T3 (de)
IL (1)	IL169016A (de)
MX (1)	MXPA05006243A (de)
NO (1)	NO331495B1 (de)
NZ (1)	NZ540449A (de)
SE (1)	SE0203754D0 (de)
WO (1)	WO2004055005A1 (de)
ZA (1)	ZA200504617B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7704995B2 (en)	2002-05-03	2010-04-27	Exelixis, Inc.	Protein kinase modulators and methods of use
SE0203753D0 (sv) *	2002-12-17	2002-12-17	Astrazeneca Ab	New compounds
SE0203752D0 (sv) *	2002-12-17	2002-12-17	Astrazeneca Ab	New compounds
DE602005020465D1 (de)	2004-08-26	2010-05-20	Pfizer	Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
ES2355923T3 (es) *	2004-08-26	2011-04-01	Pfizer, Inc.	Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa.
EP2157090A4 (de) *	2007-06-21	2011-09-07	Taisho Pharmaceutical Co Ltd	Pyrazinamidverbindung
UA103319C2 (en)	2008-05-06	2013-10-10	Глаксосмитклайн Ллк	Thiazole- and oxazole-benzene sulfonamide compounds
EP2138485A1 (de) *	2008-06-26	2009-12-30	sanofi-aventis	Substituierte N-Oxid-Pyrazin-Derivate
CA2743134A1 (en)	2008-11-10	2010-05-14	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
ES2921576T3 (es)	2008-12-19	2022-08-29	Vertex Pharma	Compuestos útiles como inhibidores de la quinasa ATR
US20110118275A1 (en) *	2009-11-13	2011-05-19	Astrazeneca Ab	OXAZOLO[4,5-c]PYRIDINE SUBSTITUTED PYRAZINE
KR20120120307A (ko) *	2010-01-19	2012-11-01	아스트라제네카 아베	피라진 유도체
NZ603477A (en)	2010-05-12	2014-09-26	Vertex Pharma	Compounds useful as inhibitors of atr kinase
EP2568984A1 (de)	2010-05-12	2013-03-20	Vertex Pharmaceuticals Incorporated	Als art-kinasehemmer nützliche verbindungen
CA2798760A1 (en)	2010-05-12	2011-11-17	Vertex Pharmaceuticals Incorporated	2-aminopyridine derivatives useful as inhibitors of atr kinase
US8962631B2 (en)	2010-05-12	2015-02-24	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
US9062008B2 (en)	2010-05-12	2015-06-23	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
US9334244B2 (en)	2010-05-12	2016-05-10	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
MX2013000103A (es)	2010-06-23	2013-06-13	Vertex Pharma	Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art.
MX2013011450A (es)	2011-04-05	2014-02-03	Vertex Pharma	Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
LT2714677T (lt)	2011-05-23	2018-12-10	Merck Patent Gmbh	Piridino ir pirazino dariniai
JP6050335B2 (ja)	2011-05-23	2016-12-21	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	チアゾール誘導体
US9309250B2 (en)	2011-06-22	2016-04-12	Vertex Pharmaceuticals Incorporated	Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
US8822469B2 (en)	2011-06-22	2014-09-02	Vertex Pharmaceuticals Incorporated	Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
EP2723747A1 (de)	2011-06-22	2014-04-30	Vertex Pharmaceuticals Inc.	Als art-kinasehemmer nützliche verbindungen
DE102011112978A1 (de)	2011-09-09	2013-03-14	Merck Patent Gmbh	Benzonitrilderivate
WO2013049722A1 (en)	2011-09-30	2013-04-04	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
CN108685922A (zh)	2011-09-30	2018-10-23	沃泰克斯药物股份有限公司	用atr抑制剂治疗胰腺癌和非小细胞肺癌
CN106496173A (zh)	2011-09-30	2017-03-15	沃泰克斯药物股份有限公司	用于制备可用作atr激酶抑制剂的化合物的方法
US8765751B2 (en)	2011-09-30	2014-07-01	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
WO2013049720A1 (en)	2011-09-30	2013-04-04	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
JP2015502925A (ja)	2011-11-09	2015-01-29	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ａｔｒキナーゼの阻害剤として有用なピラジン化合物
US8846917B2 (en)	2011-11-09	2014-09-30	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
US8841450B2 (en)	2011-11-09	2014-09-23	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
US8841337B2 (en)	2011-11-09	2014-09-23	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
US8846918B2 (en)	2011-11-09	2014-09-30	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
DE102011119127A1 (de)	2011-11-22	2013-05-23	Merck Patent Gmbh	3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
US9045493B2 (en)	2012-02-09	2015-06-02	Merck Patent Gmbh	Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives
CN108478577A (zh)	2012-04-05	2018-09-04	沃泰克斯药物股份有限公司	可用作atr激酶抑制剂的化合物及其组合疗法
DK2904406T3 (en)	2012-10-04	2018-06-18	Vertex Pharma	METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
EP2909202A1 (de)	2012-10-16	2015-08-26	Vertex Pharmaceuticals Incorporated	Als atr-kinaseinhibitoren nützliche verbindungen
SI2941432T1 (en)	2012-12-07	2018-07-31	Vertex Pharmaceuticals Incorporated	2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
WO2014143240A1 (en)	2013-03-15	2014-09-18	Vertex Pharmaceuticals Incorporated	Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
PT3077397T (pt)	2013-12-06	2020-01-22	Vertex Pharma	Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
CA2945263A1 (en)	2014-04-09	2015-10-15	Christopher Rudd	Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
MX373102B (es)	2014-06-05	2020-04-17	Vertex Pharma	Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo.
SG11201610500WA (en)	2014-06-17	2017-01-27	Vertex Pharma	Method for treating cancer using a combination of chk1 and atr inhibitors
JO3589B1 (ar)	2014-08-06	2020-07-05	Novartis Ag	مثبطات كيناز البروتين c وطرق استخداماتها
US10472347B2 (en)	2014-11-18	2019-11-12	Merck Sharp & Dohme Corp.	Aminopyrazine compounds with A2A antagonist properties
AU2016331955B2 (en)	2015-09-30	2022-07-21	Vertex Pharmaceuticals Incorporated	Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MA26473A1 (fr) *	1997-03-01	2004-12-20	Glaxo Group Ltd	Composes pharmacologiquement actifs.
PL365238A1 (en) *	2000-02-16	2004-12-27	Neurogen Corporation	Substituted arylpyrazines
TR200401217T4 (tr) *	2000-03-07	2004-06-21	Aventis Pharma Deutschland Gmbh	İkameli 3-Fenil-5-Alkoksi-1,3,4-Oksdiazol-2-one (ve) hormona duyarlı lipazın önlenmesinde kullanılması
AR029489A1 (es)	2000-03-10	2003-07-02	Euro Celtique Sa	Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
EP1406884A1 (de) *	2001-05-11	2004-04-14	Biovitrum Ab	Arylsulfonamid verbindungen zur behandlung von obesitas, typ-ii-diabetes und erkrankungen des zns
SE0102439D0 (sv) *	2001-07-05	2001-07-05	Astrazeneca Ab	New compounds
SE0102438D0 (sv) *	2001-07-05	2001-07-05	Astrazeneca Ab	New compounds
JP2003081937A (ja) *	2001-09-07	2003-03-19	Bayer Ag	ベンゼンスルホンアミド誘導体
SE0203752D0 (sv) *	2002-12-17	2002-12-17	Astrazeneca Ab	New compounds

2002
- 2002-12-17 SE SE0203754A patent/SE0203754D0/xx unknown
2003
- 2003-12-15 AT AT03781204T patent/ATE454382T1/de not_active IP Right Cessation
- 2003-12-15 NZ NZ540449A patent/NZ540449A/en not_active IP Right Cessation
- 2003-12-15 KR KR1020057011137A patent/KR101110457B1/ko not_active Expired - Fee Related
- 2003-12-15 DE DE60330910T patent/DE60330910D1/de not_active Expired - Lifetime
- 2003-12-15 EP EP09180635A patent/EP2161265A3/de not_active Withdrawn
- 2003-12-15 CA CA2508042A patent/CA2508042C/en not_active Expired - Fee Related
- 2003-12-15 CN CNB2003801066631A patent/CN100351250C/zh not_active Expired - Fee Related
- 2003-12-15 AU AU2003287135A patent/AU2003287135B2/en not_active Ceased
- 2003-12-15 BR BR0317294-5A patent/BR0317294A/pt not_active IP Right Cessation
- 2003-12-15 US US10/539,543 patent/US7585853B2/en not_active Expired - Fee Related
- 2003-12-15 JP JP2004560223A patent/JP4674088B2/ja not_active Expired - Fee Related
- 2003-12-15 WO PCT/SE2003/001955 patent/WO2004055005A1/en not_active Ceased
- 2003-12-15 MX MXPA05006243A patent/MXPA05006243A/es active IP Right Grant
- 2003-12-15 ES ES03781204T patent/ES2337682T3/es not_active Expired - Lifetime
- 2003-12-15 EP EP03781204A patent/EP1575938B1/de not_active Expired - Lifetime
2005
- 2005-06-06 IL IL169016A patent/IL169016A/en not_active IP Right Cessation
- 2005-07-15 NO NO20053460A patent/NO331495B1/no not_active IP Right Cessation
2006
- 2006-01-16 ZA ZA200504617A patent/ZA200504617B/en unknown
2009
- 2009-08-21 US US12/545,213 patent/US20100075989A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20060116362A1 (en)	2006-06-01
WO2004055005A1 (en)	2004-07-01
AU2003287135B2 (en)	2007-01-25
BR0317294A (pt)	2005-11-08
CN1729185A (zh)	2006-02-01
IL169016A (en)	2013-08-29
US20100075989A1 (en)	2010-03-25
CA2508042A1 (en)	2004-07-01
EP1575938B1 (de)	2010-01-06
JP2006513180A (ja)	2006-04-20
US7585853B2 (en)	2009-09-08
EP1575938A1 (de)	2005-09-21
HK1080856A1 (en)	2006-05-04
EP2161265A2 (de)	2010-03-10
KR101110457B1 (ko)	2012-02-17
EP2161265A3 (de)	2010-06-02
ES2337682T3 (es)	2010-04-28
NO331495B1 (no)	2012-01-16
AU2003287135A1 (en)	2004-07-09
ZA200504617B (en)	2006-03-29
NZ540449A (en)	2008-02-29
JP4674088B2 (ja)	2011-04-20
DE60330910D1 (de)	2010-02-25
KR20050084363A (ko)	2005-08-26
SE0203754D0 (sv)	2002-12-17
NO20053460L (no)	2005-08-12
CA2508042C (en)	2012-01-10
MXPA05006243A (es)	2005-08-19
WO2004055005A8 (en)	2005-06-30
CN100351250C (zh)	2007-11-28

Legal Events

Date	Code	Title	Description
2010-07-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE454382T1 (de)	2010-01-15	Verbindungen mit selektiverinhibierender wirkung für gsk3
AR034268A1 (es)	2004-02-18	Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion
NZ514234A (en)	2004-02-27	N-cyanomethylamides as protease inhibitors
NO20025641D0 (no)	2002-11-22	Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
YU31303A (sh)	2006-05-25	Jedinjenja imidazola sa pripojenim arilom ili heteroarilom kao anti-inflamatorni i analgetički agensi
MXPA03007249A (es)	2005-02-14	Compuestos triazolo como inhibidores de mmp.
ES2055860T3 (es)	1994-09-01	Derivados 2-aminopirimidinona.
GEP20063890B (en)	2006-08-10	Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
CY1110904T1 (el)	2015-06-10	Φαρμακευτικως ενεργα παραγωγα βενζοσουλφοναμιδιου ως αναστολεις πρωτεϊνικων κινασων jun
UY27368A1 (es)	2003-01-31	Nuevos compuestos
MXPA05011710A (es)	2006-01-23	Derivados de pirimidina con actividad de crf.
NZ511903A (en)	2002-12-20	Use of alpha-keto enamine derivatives as ingredients
AR032781A1 (es)	2003-11-26	Amidas ariladas de acidos furan- y tiofencarboxilicos, composiciones farmaceuticas, su utilizacion para la preparacion de medicamento como tambien las composiciones farmaceuticas que las contienen
NO20045486L (no)	2005-02-02	Nye forbindelser og deres anvendelse
MXPA04000456A (es)	2004-03-18	Analogos de prostaglandina como agonistas del receptor ep4.
AR036045A1 (es)	2004-08-04	Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, su empleo para la preparacion de un medicamento, asi como composiciones farmaceuticas que las contienen
NO20025640D0 (no)	2002-11-22	Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
NO20015172L (no)	2002-01-23	1-metyl-erytromycin-derivater
SE0100569D0 (sv)	2001-02-20	New compounds
DZ1694A1 (fr)	2002-02-17	"n-(2-Aminoethyl)-benzothialozones".
GEP20053505B (en)	2005-05-10	Diphenyl Ether Compounds Useful in Therapy
SE0201194D0 (sv)	2002-04-19	New compounds
SE0102440D0 (sv)	2001-07-05	New compound
MXPA04005313A (es)	2004-09-13	Derivados de aminotetralin como antagonistas del receptor muscarinico.
UY27324A1 (es)	2003-02-28	Nuevas sales de napsilato i